Skip to content

A Multi-center, Prospective, Randomized, Controlled Trial for the Safety of Endocrine Function, Fertility Function Surgery and Drug Therapy for Endometrial Atypical Hyperplasia and Stage IA Endometrial Carcinoma

A Multi-center, Prospective, Randomized, Controlled Trial for the Safety of Endocrine Function, Fertility Function Surgery and Drug Therapy for Endometrial Atypical Hyperplasia and Stage IA Endometrial Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016513
Enrollment
Unknown
Registered
2018-06-05
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometrial cancer

Interventions

fertility group:fertility-sparing surgery
ovarian preservation group:ovarian preservation surgery
Endometrial cancer radical surgery group:Endometrial cancer radical surgery

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Premenopausal women, age = 50 years; 2. Surgical curettage / hysteroscopic pathology confirmed, endometrioid adenocarcinoma G1/G2 (including well-differentiated, high-medium and middle-differentiation); 3. Clinical consideration of IA (<1/2 muscle infiltration); 4. First-time treatment; 5. The subject (or his legal representative) must understand the nature of the study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. At the same time participate in other clinical trials; 2. Can not tolerate surgery; 3. Ovarian suspicious metastasis; 4. Have a family history of ovarian cancer; 5. Incorporate other malignant tumors; 6. Preoperative CA125 abnormal persons.

Design outcomes

Primary

MeasureTime frame
Progression Free Survival;Total survival time;

Secondary

MeasureTime frame
Gynecological endocrine function evaluation;Ovarian volume;

Countries

China

Contacts

Public ContactMin Wang
wm21st@126.com+86 18940251222

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026